Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:APLIFNASDAQ:GLMDNASDAQ:NCNANYSEAMERICAN:NTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLIFAppili Therapeutics$0.01$0.02$0.01▼$0.03$1.49M-0.685,603 shsN/AGLMDGalmed Pharmaceuticals$1.60-0.6%$1.41$1.15▼$23.80$2.65M0.511.31 million shs299,774 shsNCNANuCana$0.11-24.4%$0.35$0.03▼$10.79$698K1.2433.59 million shs116.86 million shsNTNNTN Buzztime$2.29-3.4%$0.25$0.94▼$7.76$6.82M0.721.63 million shs108,371 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLIFAppili Therapeutics-0.41%+14.49%-41.11%-46.74%-60.29%GLMDGalmed Pharmaceuticals0.00%+5.96%+26.98%-7.35%-62.96%NCNANuCana0.00%+130.26%+115.17%-84.89%-96.21%NTNNTN Buzztime-3.38%+1,172.22%+945.66%+791.40%+19.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLIFAppili TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGLMDGalmed Pharmaceuticals1.0839 of 5 stars0.02.00.00.03.32.50.6NCNANuCana3.3557 of 5 stars3.34.00.00.02.72.51.3NTNNTN BuzztimeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLIFAppili Therapeutics 0.00N/AN/AN/AGLMDGalmed Pharmaceuticals 2.00HoldN/AN/ANCNANuCana 2.50Moderate Buy$25.0021,658.05% UpsideNTNNTN Buzztime 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NTN, GLMD, APLIF, and NCNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025GLMDGalmed PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLIFAppili Therapeutics$630K2.36N/AN/A($0.05) per share-0.25GLMDGalmed PharmaceuticalsN/AN/AN/AN/A$33.02 per shareN/ANCNANuCanaN/AN/AN/AN/A$8.85 per shareN/ANTNNTN Buzztime$19.81M0.34$0.52 per share4.38$1.76 per share1.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLIFAppili Therapeutics-$2.80M-$0.02N/A∞N/AN/AN/A-209.09%N/AGLMDGalmed Pharmaceuticals-$6.91M-$16.66N/A∞N/AN/A-28.75%-24.98%8/26/2025 (Estimated)NCNANuCana-$34.37M-$7.02N/AN/AN/AN/A-314.47%-112.60%8/13/2025 (Estimated)NTNNTN Buzztime-$2.05MN/AN/A∞N/A-61.42%-162.54%-49.94%N/ALatest NTN, GLMD, APLIF, and NCNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2025Q1 2025NCNANuCana-$0.0129-$0.63-$0.6171-$0.63N/AN/A5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A3/20/2025Q4 2024NCNANuCana-$2.43-$0.32+$2.11-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLIFAppili TherapeuticsN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ANTNNTN BuzztimeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLIFAppili TherapeuticsN/A0.110.11GLMDGalmed PharmaceuticalsN/A7.037.03NCNANuCanaN/A1.121.12NTNNTN Buzztime3.300.950.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLIFAppili TherapeuticsN/AGLMDGalmed Pharmaceuticals76.14%NCNANuCana44.00%NTNNTN Buzztime6.31%Insider OwnershipCompanyInsider OwnershipAPLIFAppili Therapeutics11.84%GLMDGalmed Pharmaceuticals19.80%NCNANuCana31.20%NTNNTN Buzztime24.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLIFAppili Therapeutics8121.27 million106.91 millionNot OptionableGLMDGalmed Pharmaceuticals201.65 million516,000Not OptionableNCNANuCana306.08 million1.82 millionNot OptionableNTNNTN Buzztime192.98 millionN/ANot OptionableNTN, GLMD, APLIF, and NCNA HeadlinesRecent News About These CompaniesNTN Buzztime (NYSEAMERICAN:NTN) Shares Cross Above 200 Day Moving Average - What's Next?June 5, 2025 | americanbankingnews.comEterna Therapeutics sets annual meeting date, opens nominationsFebruary 13, 2025 | msn.comBryant FBLA students to host yard sale, Big Blue Market on April 20April 5, 2024 | bentoncourier.comThe Petri Dish: Boston biotech scores FDA approval, antiviral maker stops 3 studiesDecember 28, 2023 | bizjournals.comExclusive: RNA firm Eterna Therapeutics buys neighboring startup for $50MMay 2, 2023 | bizjournals.comBrooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial ResultsApril 15, 2022 | ca.finance.yahoo.comA list of mental health startups in the Pacific Northwest, as pandemic fuels growth for sectorMarch 23, 2022 | geekwire.comMy Buzzcard LoginJanuary 13, 2022 | c21media.netTop 10 Penny Stocks of 2017October 26, 2021 | finance.yahoo.comEveryone from pharma giants to startup biotechs wants in on the hottest way to develop drugsOctober 6, 2021 | msn.comDemocrats push to retool health care programs for millionsSeptember 21, 2021 | sandiegouniontribune.comSporcle Events: A New BeginningAugust 31, 2021 | sporcle.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTN, GLMD, APLIF, and NCNA Company DescriptionsAppili Therapeutics OTCMKTS:APLIF$0.01 0.00 (0.00%) As of 06/13/2025Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.Galmed Pharmaceuticals NASDAQ:GLMD$1.60 -0.01 (-0.62%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.62 +0.02 (+1.25%) As of 06/13/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.NuCana NASDAQ:NCNA$0.11 -0.04 (-24.41%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.12 +0.01 (+5.31%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.NTN Buzztime NYSEAMERICAN:NTN$2.29 -0.08 (-3.38%) As of 06/13/2025NTN Buzztime, Inc., together with its subsidiaries, provides interactive entertainment and technology to bars, restaurants, casinos, and senior living centers in the United States and Canada. Its principal product and service is its tablet platform. The company also leases equipment, including tablets, and cases and charging trays for the tablets to various network subscribers. It also licenses its content to customers to be installed on equipment that they obtain from other parties. The company's interactive entertainment system offers trivia, card, sports, and arcade games. It owns various trademarks, including the Buzztime, Playmaker, Mobile Playmaker, and BEOND Powered. As of June 30, 2020, NTN Buzztime, Inc. served 1,219 venues with its interactive entertainment network. The company was formerly known as NTN Communications, Inc. and changed its name to NTN Buzztime, Inc. in 2005. NTN Buzztime, Inc. was founded in 1982 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
